TY - JOUR
T1 - Consolidative thoracic radiotherapy and prophylactic cranial irradiation in limited disease small cell lung cancer
AU - Slotman, B J
AU - Njo, K H
AU - de Jonge, A
AU - Meyer, O W
AU - Karim, A B
PY - 1993/12
Y1 - 1993/12
N2 - Between 1983 and 1990, 128 patients with limited disease small cell lung cancer (SCLC) received consolidative thoracic irradiation after reaching a complete (CR) or partial response (PR) to combination chemotherapy. Patients in CR (n = 85) received 35-36 Gy in 12-14 fractions and patients in PR (n = 43) 24-30 Gy in 3-6 fractions. Until 1989, prophylactic cranial irradiation (PCI) was given to patients in CR. There was no significant difference in survival between the CR and PR group. However, patients with residual tumor detected by radiology or bronchoscopy or cyto-/histology had significantly longer survival than those with residual tumor demonstrated by more than one of the above methods of investigation. Overall, local progression was observed in 22% and distant dissemination in 63% of patients. The rate of brain metastases was significantly lower in patients treated with methotrexate and nitrosurea containing schedules and PCI, compared to those who were treated with other schedules (irrespective of PCI).
AB - Between 1983 and 1990, 128 patients with limited disease small cell lung cancer (SCLC) received consolidative thoracic irradiation after reaching a complete (CR) or partial response (PR) to combination chemotherapy. Patients in CR (n = 85) received 35-36 Gy in 12-14 fractions and patients in PR (n = 43) 24-30 Gy in 3-6 fractions. Until 1989, prophylactic cranial irradiation (PCI) was given to patients in CR. There was no significant difference in survival between the CR and PR group. However, patients with residual tumor detected by radiology or bronchoscopy or cyto-/histology had significantly longer survival than those with residual tumor demonstrated by more than one of the above methods of investigation. Overall, local progression was observed in 22% and distant dissemination in 63% of patients. The rate of brain metastases was significantly lower in patients treated with methotrexate and nitrosurea containing schedules and PCI, compared to those who were treated with other schedules (irrespective of PCI).
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Brain Neoplasms/mortality
KW - Carboplatin/administration & dosage
KW - Carcinoma, Small Cell/drug therapy
KW - Chemotherapy, Adjuvant
KW - Combined Modality Therapy
KW - Cranial Irradiation
KW - Cyclophosphamide/administration & dosage
KW - Doxorubicin/administration & dosage
KW - Epirubicin/administration & dosage
KW - Etoposide/administration & dosage
KW - Lomustine/administration & dosage
KW - Lung Neoplasms/drug therapy
KW - Methotrexate/administration & dosage
KW - Remission Induction
KW - Survival Analysis
KW - Thorax/radiation effects
KW - Treatment Outcome
KW - Vincristine/administration & dosage
M3 - Article
C2 - 8075967
VL - 10
SP - 199
EP - 208
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
IS - 3-4
ER -